SCHEDULE 13G/A: ARK Investment Management and Catherine Wood Disclose 11.85% Stake in CRISPR Therapeutics AG

ARK Investment Management LLC and Catherine D. Wood have jointly filed an Amendment No. 11 to Schedule 13G, disclosing a combined beneficial ownership of 11.85% in CRISPR Therapeutics AG as of March 31, 2025.

Summary

• ARK Investment Management LLC and Catherine D. Wood, acting as reporting persons, have filed an Amendment No. 11 to Schedule 13G regarding their beneficial ownership in CRISPR Therapeutics AG.
• As of March 31, 2025, the reporting persons collectively beneficially own 10,165,400 shares of CRISPR Therapeutics AG's Common Stock.
• This aggregate amount represents 11.85% of the class of securities.
• ARK Investment Management LLC holds sole voting power over 9,547,322 shares and sole dispositive power over 10,165,400 shares.
• Catherine D. Wood holds shared voting power over 9,768,503 shares and shared dispositive power over 10,165,400 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• ARK Innovation ETF, a series of a Delaware statutory trust, is noted as a client of ARK Investment Management LLC with an interest in the securities exceeding 5 percent.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the disclosure of a significant stake by a prominent investment firm, which can be interpreted as a vote of confidence, although the document itself is purely factual and regulatory.

Positives

• The disclosure of a significant stake (11.85%) by a prominent investment firm like ARK Investment Management and its CEO, Catherine D. Wood, may signal confidence in CRISPR Therapeutics AG's future prospects.
• The filing confirms that the stake is held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent to influence control.

Negatives

• NA

Risks

• NA

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

The disclosure of a significant stake by ARK Investment Management, known for its focus on disruptive innovation, highlights continued investor interest in the biotechnology and gene-editing sector, where CRISPR Therapeutics AG is a key player.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership as required by SEC regulations for investors holding more than 5% of a company's stock. It does not provide performance metrics for comparison.

Related Party Transactions

• ARK Investment Management LLC and Catherine D. Wood have entered into a joint filing agreement for this Schedule 13G Amendment No. 11.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by ARK Investment Management and Catherine D. Wood may influence investor sentiment and potentially the stock price, signaling institutional confidence in CRISPR Therapeutics AG.
• Company Management: Awareness of a large, passive institutional holder like ARK may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

CRISPR Therapeutics AG, ARK Investment Management LLC, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Gene Editing